Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

NCT04854096 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped The study was stopped due to a business decision.

Conditions

Primary Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Post-polycythemia Vera Myelofibrosis

Interventions

DRUG: NS-018
DRUG: Best Available Therapy

Sponsor

NS Pharma, Inc.

Collaborators

[object Object]